; table of contents. Title I—Ending Surprise Medical Bills Sec. 101. Protecting patients against out-of-network deductibles in emergencies. Sec. 102. Protection against surprise bills. Sec. 103. Benchmark for payment. Sec. 104. Effective date. Sec. 105. Ending surprise air ambulance bills. Sec. 106. Report. Title II—Reducing the Prices of Prescription Drugs Sec. 201. Biological product patent transparency. Sec. 202. Orange book modernization. Sec. 203. Ensuring timely access to generics. Sec. 204. Protecting access to biological products. Sec. 205. Preventing blocking of generic drugs. Sec. 206. Education on biological products. Sec. 207. Biological product innovation. Sec. 208. Clarifying the meaning of new chemical entity. Sec. 209. Streamlining the transition of biological products. Sec. 210. Orphan drug clarification. Sec. 211. Prompt approval of drugs related to safety information. Sec. 212. Conditions of use for biosimilar biological products. Sec. 213. Modernizing the labeling of certain generic drugs. Title III—Improving Transparency in Health Care Sec. 301. Increasing transparency by removing gag clauses on price and quality information. Sec. 302. Banning anticompetitive terms in facility and insurance contracts that limit access to higher quality, lower cost care. Sec. 303. Designation of a nongovernmental, nonprofit transparency organization to lower Americans’ health care costs. Sec. 304. Protecting patients and improving the accuracy of provider directory information. Sec. 305. Timely bills for patients. Sec. 306. Health plan oversight of pharmacy benefit manager services. Sec. 307. Government Accountability Office study on profit- and revenue-sharing in health care. Sec. 308. Disclosure of direct and indirect compensation for brokers and consultants to employer-sponsored health plans and enrollees in plans on the individual market. Sec. 309. Ensuring enrollee access to cost-sharing information. Sec. 310. Strengthening parity in mental health and substance use disorder benefits. Sec. 311. Technical